Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R. (2015). Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. Journal of Clinical Oncology, 33(32), 3817–3825. https://doi.org/10.1200/JCO.2015.61.5997

Article  PubMed  PubMed Central  CAS  Google Scholar 

O’Dwyer, P. J., Gray, R. J., Flaherty, K. T., Chen, A. P., Li, S., Wang, V., McShane, L. M., Patton, D. R., Tricoli, J. V., Williams, P. M., Iafrate, A. J., Sklar, J., Mitchell, E. P., Takebe, N., Sims, D. J., Coffey, B., Fu, T., Routbort, M., Rubinstein, L. V., … Doroshow, J. H. (2023). The NCI-MATCH trial: Lessons for precision oncology. Nature Medicine, 29(6), 1349–1357. https://doi.org/10.1038/s41591-023-02379-4

Meric-Bernstam, F., Ford, J. M., O’Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O’Cearbhaill, R. E., George, S., Glade-Bender, J., Lyman, G. H., Tricoli, J. V., Patton, D., Hamilton, S. R., Gray, R. J., Hawkins, D. S., Ramineni, B., Flaherty, K. T., Grivas, P., Yap, T. A., … on behalf of ComboMATCH study team. (2023). National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clinical Cancer Research, 29(8), 1412–1422. https://doi.org/10.1158/1078-0432.CCR-22-3334

Middleton, G., Marshall, L., Billingham, L., Duffus, K. D., Greystoke, A., Carter, L., Forster, M. D., Cook, N., Hargrave, D., Danson, S., Roxburgh, P., Beggs, A. D., Chaturvedi, A., Chesler, L., Sarmiento-Castro, A., Dive, C., Rothwell, D., Gath, J., Halford, S., & Krebs, M. G. (2023). 716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers. Annals of Oncology, 34, S494–S495. https://doi.org/10.1016/j.annonc.2023.09.1902

Article  Google Scholar 

Adashek, J. J., Subbiah, V., & Kurzrock, R. (2021). From tissue-agnostic to N-of-one therapies: (R)Evolution of the precision paradigm. Trends in Cancer, 7(1), 15–28. https://doi.org/10.1016/j.trecan.2020.08.009

Article  PubMed  CAS  Google Scholar 

Redig, A. J., & Jänne, P. A. (2015). Basket trials and the evolution of clinical trial design in an era of genomic medicine. Journal of Clinical Oncology, 33(9), 975–977. https://doi.org/10.1200/JCO.2014.59.8433

Article  PubMed  CAS  Google Scholar 

Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine. Genome Medicine, 14(1), 101. https://doi.org/10.1186/s13073-022-01102-1

Article  PubMed  PubMed Central  Google Scholar 

Manea, C. A., Badiu, D. C., Ploscaru, I. C., Zgura, A., Bacinschi, X., Smarandache, C. G., Serban, D., Popescu, C. G., Grigorean, V. T., & Botnarciuc, V. (2022). A review of NTRK fusions in cancer. Annals of Medicine and Surgery, 79. https://doi.org/10.1016/j.amsu.2022.103893

Cocco, E., Scaltriti, M., & Drilon, A. (2018). NTRK fusion-positive cancers and TRK inhibitor therapy. Nature Reviews Clinical Oncology, 15(12), 731–747. https://doi.org/10.1038/s41571-018-0113-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., … Hyman, D. M. (2018). Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. New England Journal of Medicine, 378(8), 731–739. https://doi.org/10.1056/NEJMoa1714448

Hong, D. S., Drilon, A. E., Tan, D. S.-W., Lin, J. J., Kummar, S., McDermott, R. S., Berlin, J., Italiano, A., Lassen, U. N., Leyvraz, S., Tahara, M., Norenberg, R., Burcoveanu, D.-I., Brega, N., & Shen, L. (2023). Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. Journal of Clinical Oncology, 41(16_suppl), 3141–3141. https://doi.org/10.1200/JCO.2023.41.16_suppl.3141

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., Besse, B., Chawla, S. P., Bazhenova, L., Krauss, J. C., Chae, Y. K., Barve, M., Garrido-Laguna, I., Liu, S. V., Conkling, P., … Demetri, G. D. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1–2 trials. The Lancet Oncology, 21(2), 271–282. https://doi.org/10.1016/S1470-2045(19)30691-6

Krzakowski, M. J., Lu, S., Cousin, S., Smit, E. F., Springfeld, C., Goto, K., Garrido, P., Chung, C. H., Lin, J. J., Bray, V. J., Pitcher, B., Zeuner, H., Patel, S., Bordogna, W., & Gelderblom, H. (2022). Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. Journal of Clinical Oncology, 40(16_suppl), 3099–3099. https://doi.org/10.1200/JCO.2022.40.16_suppl.3099

Solomon, B. J., Drilon, A., Lin, J. J., Bazhenova, L., Goto, K., Langen, J. D., Kim, D.-W., Wolf, J., Springfeld, C., Popat, S., Lim, D.W.-T., Baik, C. S., Hervieu, A., Garcia, V. M., Yang, N., Thamake, S., Ades, F., Trone, D., & Besse, B. (2023). 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial. Annals of Oncology, 34, S787–S788. https://doi.org/10.1016/j.annonc.2023.09.2405

Article  Google Scholar 

Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020). Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes, 11(11), 11. https://doi.org/10.3390/genes11111342

Article  CAS  Google Scholar 

Pisapia, P., Pepe, F., Iaccarino, A., Sgariglia, R., Nacchio, M., Russo, G., Gragnano, G., Malapelle, U., & Troncone, G. (2020). BRAF: A two-faced Janus. Cells, 9(12), 12. https://doi.org/10.3390/cells9122549

Article  CAS  Google Scholar 

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., Italiano, A., Yonemori, K., Cho, D. C., de Vos, F. Y. F. L., Moreau, P., Fernandez, E. E., Schellens, J. H. M., Zielinski, C. C., Redhu, S., … Bang, Y.-J. (2023). Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial. Nature Medicine, 29(5), 1103–1112. https://doi.org/10.1038/s41591-023-02321-8

Salama, A. K. S., Li, S., Macrae, E. R., Park, J.-I., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Armstrong, D. K., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., & Flaherty, K. T. (2020). Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology, 38(33), 3895–3904. https://doi.org/10.1200/JCO.20.00762

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bouffet, E., Geoerger, B., Moertel, C., Whitlock, J. A., Aerts, I., Hargrave, D., Osterloh, L., Tan, E., Choi, J., Russo, M., & Fox, E. (2023). Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600–mutant low-grade glioma. Journal of Clinical Oncology, 41(3), 664–674. https://doi.org/10.1200/JCO.22.01000

Article  PubMed  CAS  Google Scholar 

Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F. (2020). State-of-the-art strategies for targeting RET-dependent cancers. Journal of Clinical Oncology, 38(11), 1209–1221. https://doi.org/10.1200/JCO.19.02551

Article  PubMed  PubMed Central  CAS  Google Scholar 

Takahashi, M., Kawai, K., & Asai, N. (2020). Roles of the RET proto-oncogene in cancer and development. JMA Journal, 3(3), 175–181. https://doi.org/10.31662/jmaj.2020-0021

Article  PubMed  PubMed Central  Google Scholar 

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y.-J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., … Subbiah, V. (2020). Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. New England Journal of Medicine, 383(9), 813–824. https://doi.org/10.1056/NEJMoa2005653

Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., Patel, J., Leboulleux, S., Godbert, Y., Barlesi, F., Morris, J. C., Owonikoko, T. K., Tan, D. S. W., Gautschi, O., Weiss, J., Fouchardière, C. de la, Burkard, M. E., … Cabanillas, M. E. (2020). Efficacy of selpercatinib in RET-altered thyroid cancers. New England Journal of Medicine, 383(9), 825–835. https://doi.org/10.1056/NEJMoa2005651

Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., Soldatenkova, V., Szymczak, S., Sullivan, L., Wright, J., & Drilon, A. (2022). Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial. The Lancet Oncology, 23(10), 1261–1273. https://doi.org/10.1016/S1470-2045(22)00541-1

Article  PubMed  PubMed Central  CAS  Google Scholar 

Subbiah, V., Drilon, A. E., Sukrithan, V., Spira, A. I., Robinson, B., Deschler-Baier, B., Barker, S., Lin, Y., Szymczak, S., & Ohe, Y. (2024). Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001. Journal of Clinical Oncology, 42(3_suppl), 746–746. https://doi.org/10.1200/JCO.2024.42.3_suppl.746

Article  Google Scholar 

Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., Garralda, E., Paz-Ares, L. G., Cho, B. C., Gadgeel, S. M., Thomas, M., Liu, S. V., Taylor, M. H., Mansfield, A. S., Zhu, V. W., … Subbiah, V. (2021). Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): A multi-cohort, open-label, phase 1/2 study. The Lancet Oncology, 22(7), 959–969. https://doi.org/10.1016/S1470-2045(21)00247-3

Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C.-C., Godbert, Y., … Taylor, M. H. (2021). Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. The Lancet Diabetes & Endocrinology, 9(8), 491–501. https://doi.org/10.1016/S2213-8587(21)00120-0

Subbiah, V., Cassier, P. A., Siena, S., Garralda, E., Paz-Ares, L., Garrido, P., Nadal, E., Vuky, J., Lopes, G., Kalemkerian, G. P., Bowles, D. W., Seetharam, M., Chang, J., Zhang, H., Green, J., Zalutskaya, A., Schuler, M., Fan, Y., & Curigliano, G. (2022). Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial. Nature Medicine, 28(8), 1640–1645. https://doi.org/10.1038/s41591-022-01931-y

Article  PubMed  PubMed Central  CAS  Google Scholar 

Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Molecular Biology International, 2014, 852748. https://doi.org/10.1155/2014/852748

Article  PubMed  PubMed Central  CAS  Google Scholar 

Keam, S. J. (2020). Trastuzumab Deruxtecan: First Approval. Drugs, 80(5), 501–508. https://doi.org/10.1007/s40265-020-01281-4

Article  PubMed  CAS  Google Scholar 

Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., Melichar, B., Siena, S., Stroyakovskiy, D., Fielding, A., Ma, Y., Puvvada, S., Shire, N., & Lee, J.-Y. (2024). Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. Journal of Clinical Oncology, 42(1), 47–58. https://doi.org/10.1200/JCO.23.02005

Article  PubMed  CAS  Google Scholar 

Smit, E. F., Felip, E., Uprety, D., Nagasaka, M., Nakagawa, K., Rodríguez, L.P.-A., Pacheco, J. M., Li, B. T., Planchard, D., Baik, C., Goto, Y., Murakami, H., Saltos, A., Pereira, K., Taguchi, A., Cheng, Y., Yan, Q., Feng, W., Tsuchihashi, Z., & Jänne, P. A. (2024). Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. The Lancet Oncology, 25(4), 439–454. https://doi.org/10.1016/S1470-2045(24)00064-0

Article  PubMed  CAS  Google Scholar 

Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., Van Den Eynde, M., Di Bartolomeo, M., Komatsu, Y., Kawakami, H., Peeters, M., Andre, T., Lonardi, S., Yamaguchi, K., Tie, J., Gravalos Castro, C., Strickler, J. H., Barrios, D., Yan, Q., Kamio, T., Kobayashi, K., & Yoshino, T. (2023). Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. Journal of Clinical Oncology, 41(16_suppl), 3501–3501. https://doi.org/10.1200/JCO.2023.41.16_suppl.3501

Article